Latest news with #ADAM™
Business Upturn
26-04-2025
- Health
- Business Upturn
Studies Show Breakthroughs in Male Contraception, Including First Male Contraceptive Hydrogel
By GlobeNewswire Published on April 26, 2025, 20:00 IST LAS VEGAS, April 26, 2025 (GLOBE NEWSWIRE) — Groundbreaking research presented at the American Urological Association (AUA) Annual Meeting in Las Vegas is ushering in a new era for men's reproductive health. Among this year's highlights are the initial safety results from the first-in-human trial of ADAM™, an innovative hydrogel developed as a reversible, non-hormonal male contraceptive. Additionally, new findings reveal that GLP1-agonist medications, commonly used for weight management and diabetes, are associated with improved sperm counts in overweight and obese men. Together, these studies represent significant advances in both male contraception and fertility, offering hope for expanded options and improved outcomes for men worldwide. Researchers will present their study findings covering important updates on fertility and contraception from April 26 to 29. Raevti Bole, MD, a men's health urology specialist at the Cleveland Clinic, posed in-depth questions to the abstract authors, providing key insights into their research. 'These exciting studies presented at AUA2025 reflect new possibilities in male fertility and contraception research,' Dr. Bole said. 'For the first time, we're seeing promising safety results from a reversible, non-hormonal male birth control that may fit the needs of couples who need a secure contraceptive option but are not ready for something permanent. There is also some new evidence that GLP1 agonists could have additional benefits for fertility in men who are taking the medication for weight or diabetes management. Together, these findings may represent novel paths towards men's reproductive health and safe, effective family planning.' The following abstracts are spotlighted in the AUA Press Program: A recording of the key findings from the abstract authors is available to all press registrants. Fill out the registration form on the website to be added to the virtual programming: NOTE TO REPORTERS: Presenting authors and moderators are available to discuss their findings. To arrange an interview with an expert, please contact the AUA Communications Team at [email protected]. About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology and has nearly 26,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Associated Press
15-04-2025
- Business
- Associated Press
Contraline Secures 15th Issued Patent, Reinforcing IP Leadership in Male Contraception
CHARLOTTESVILLE, VA, UNITED STATES, April 15, 2025 / / -- Contraline, Inc., the leading innovator in male contraception, today announced the issuance of its 15th U.S. patent, further advancing the company's mission to develop a new standard of care in reproductive health. This milestone reflects Contraline's continued investment in building one of the most comprehensive intellectual property portfolios in the field of male contraception. With this milestone, Contraline's global patent portfolio, including those owned and licensed, has grown to 15 issued patents and more than 50 pending applications across the United States, Europe, Australia, Canada, and Asia. Contraline's flagship product is the ADAM™ hydrogel, a biocompatible hydrogel implanted in the vas deferens designed to block sperm transport. The IP portfolio spans the entire innovation lifecycle of hydrogel-based vas-occlusive contraception, from novel biomaterials and precision delivery systems to advanced imaging and minimally-invasive reversal techniques. 'This milestone underscores our commitment to leading innovation in male contraception,' said Kevin Eisenfrats, Co-Founder and CEO of Contraline. 'Our goal has always been to deliver the best possible experience for patients and physicians. Every new patent represents years of R&D and our belief that the ADAM™ hydrogel can redefine the landscape of birth control for men.' Contraline's issued and pending patents protect multiple critical components of its technology platform: Hydrogel Compositions Contraline has multiple issued patents that protect a range of hydrogel systems with tunable pore sizes and chemical and mechanical properties designed for safe, effective, and reversible sperm occlusion. These patents include, but are not limited to, two-component hydrogel compositions, which can be mixed in situ to rapidly form a stable, occlusive implant within the vas deferens. Delivery Systems Multiple patents cover proprietary injection devices featuring precision-controlled drive mechanisms, methods of delivery, and kit configurations that ensure consistent, in-office administration of the ADAM™ hydrogel. Reversal Methods Patents that cover a range of techniques for restoring fertility, including external stimuli that degrade or dissolve the hydrogel implant in situ. Contraline's patent estate includes issued patents across Europe, Canada, Australia, and Japan, with pending applications in all major international markets. While Contraline's core focus is male contraception, its underlying hydrogel platform could support broader applications—including reversible occlusion of other anatomical lumens, such as the fallopian tubes, and use in therapeutic drug delivery or vascular modulation. With 15 issued patents and a rapidly expanding pipeline of pending claims, Contraline has established itself as a clear IP leader in biomaterials-based contraception. About Contraline, Inc. Contraline, Inc. is a venture-backed, clinical-stage, biotechnology company focused on innovation in reproductive health. The company's mission is to develop novel male contraceptives that are safe, effective, appealing, and reversible. Visit Disclaimer ADAM™ The ADAM™ device is an investigational device and is not yet authorized by the U.S. Food and Drug Administration (FDA) or any other regulatory authority worldwide. As such, the ADAM™ device is not available for commercial use at this time and it is currently available only for investigational use in approved clinical trials. Kevin Eisenfrats Contraline, Inc. email us here Visit us on social media: LinkedIn Instagram Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
